The B7:CD28 Family and Friends: Unraveling Coinhibitory Interactions

Overview

Journal Immunity

Publisher Cell Press

Specialty Allergy & Immunology

Date 2024 Feb 14

PMID 38354702

Authors

Kelly P Burke

Apoorvi Chaudhri

Gordon J Freeman

Arlene H Sharpe

Affiliations

Soon will be listed here.

Abstract

Immune responses must be tightly regulated to ensure both optimal protective immunity and tolerance. Costimulatory pathways within the B7:CD28 family provide essential signals for optimal T cell activation and clonal expansion. They provide crucial inhibitory signals that maintain immune homeostasis, control resolution of inflammation, regulate host defense, and promote tolerance to prevent autoimmunity. Tumors and chronic pathogens can exploit these pathways to evade eradication by the immune system. Advances in understanding B7:CD28 pathways have ushered in a new era of immunotherapy with effective drugs to treat cancer, autoimmune diseases, infectious diseases, and transplant rejection. Here, we discuss current understanding of the mechanisms underlying the coinhibitory functions of CTLA-4, PD-1, PD-L1:B7-1 and PD-L2:RGMb interactions and less studied B7 family members, including HHLA2, VISTA, BTNL2, and BTN3A1, as well as their overlapping and unique roles in regulating immune responses, and the therapeutic potential of these insights.

Citing Articles

Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors.

Du F, Wang G, Dai Q, Huang J, Li J, Liu C Biomark Res. 2025; 13(1):35.

PMID: 40012016 PMC: 11866848. DOI: 10.1186/s40364-025-00748-4.

The m6A revolution: transforming tumor immunity and enhancing immunotherapy outcomes.

Shi T, Zhang H, Chen Y Cell Biosci. 2025; 15(1):27.

PMID: 39987091 PMC: 11846233. DOI: 10.1186/s13578-025-01368-z.

Cross-priming in cancer immunology and immunotherapy.

Luri-Rey C, Teijeira A, Wculek S, de Andrea C, Herrero C, Lopez-Janeiro A Nat Rev Cancer. 2025; .

PMID: 39881005 DOI: 10.1038/s41568-024-00785-5.

PD-L1-CD80 interactions are required for intracellular signaling necessary for dendritic cell migration.

Kantheti U, Forward T, Lucas E, Schafer J, Tamburini P, Burchill M Sci Adv. 2025; 11(5):eadt3044.

PMID: 39879305 PMC: 11777207. DOI: 10.1126/sciadv.adt3044.

- and Pathogenic Bacteria-Derived Endotoxins Differently Regulate Human Dendritic Cell Generation and γδ T Lymphocyte Activation.

Fertitta V, Varano B, Del Corno M, Fortini P, Aureli A, Conti L Biomolecules. 2025; 14(12.

PMID: 39766278 PMC: 11673428. DOI: 10.3390/biom14121571.

References

Mager D, Hunter D, Schertzer M, Freeman J . Endogenous retroviruses provide the primary polyadenylation signal for two new human genes (HHLA2 and HHLA3). Genomics. 1999; 59(3):255-63. DOI: 10.1006/geno.1999.5877. View

Zhou Q, Li K, Chen X, He H, Peng S, Peng S . HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma. J Immunother Cancer. 2020; 8(1). PMC: 7057441. DOI: 10.1136/jitc-2019-000157. View

Scott A, Dundar F, Zumbo P, Chandran S, Klebanoff C, Shakiba M . TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019; 571(7764):270-274. PMC: 7698992. DOI: 10.1038/s41586-019-1324-y. View

Jing C, Fu Y, Yi Y, Zhang M, Zheng S, Huang J . HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1. J Immunother Cancer. 2019; 7(1):77. PMC: 6421676. DOI: 10.1186/s40425-019-0554-8. View

Tong X, Ma Y, Niu X, Yan Z, Liu S, Peng B . The BTNL2 G16071A gene polymorphism increases granulomatous disease susceptibility: A meta-analysis including FPRP test of 8710 participants. Medicine (Baltimore). 2016; 95(30):e4325. PMC: 5265849. DOI: 10.1097/MD.0000000000004325. View

Wei Y, Ren X, Galbo Jr P, Moerdler S, Wang H, Sica R . KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Sci Immunol. 2021; 6(61). PMC: 9744578. DOI: 10.1126/sciimmunol.abf9792. View

Liao X, Zhang D . HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma. Am J Clin Pathol. 2022; 158(1):62-69. DOI: 10.1093/ajcp/aqab221. View

Lines J, Sempere L, Broughton T, Wang L, Noelle R . VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol Res. 2014; 2(6):510-7. PMC: 4085258. DOI: 10.1158/2326-6066.CIR-14-0072. View

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A . Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2005; 439(7077):682-7. DOI: 10.1038/nature04444. View

10.

Gu S, Sachleben J, Boughter C, Nawrocka W, Borowska M, Tarrasch J . Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on Vγ9Vδ2 T cell activation. Proc Natl Acad Sci U S A. 2017; 114(35):E7311-E7320. PMC: 5584448. DOI: 10.1073/pnas.1707547114. View

11.

Esensten J, Helou Y, Chopra G, Weiss A, Bluestone J . CD28 Costimulation: From Mechanism to Therapy. Immunity. 2016; 44(5):973-88. PMC: 4932896. DOI: 10.1016/j.immuni.2016.04.020. View

12.

Rota G, Niogret C, Dang A, Barros C, Fonta N, Alfei F . Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo. Cell Rep. 2018; 23(1):39-49. DOI: 10.1016/j.celrep.2018.03.026. View

13.

Tuttle J, Drescher E, Simon-Campos J, Emery P, Greenwald M, Kivitz A . A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis. N Engl J Med. 2023; 388(20):1853-1862. DOI: 10.1056/NEJMoa2209856. View

14.

Yu S, Leung K, Kim H, Umetsu S, Xiao Y, Albacker L . Blockade of RGMb inhibits allergen-induced airways disease. J Allergy Clin Immunol. 2019; 144(1):94-108.e11. PMC: 8088837. DOI: 10.1016/j.jaci.2018.12.1022. View

15.

Oestreich K, Yoon H, Ahmed R, Boss J . NFATc1 regulates PD-1 expression upon T cell activation. J Immunol. 2008; 181(7):4832-9. PMC: 2645436. DOI: 10.4049/jimmunol.181.7.4832. View

16.

Zhao R, Chinai J, Buhl S, Scandiuzzi L, Ray A, Jeon H . HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc Natl Acad Sci U S A. 2013; 110(24):9879-84. PMC: 3683785. DOI: 10.1073/pnas.1303524110. View

17.

Conrad S, Stimpfle F, Montazeri S, Oldekamp J, Seid K, Alvarez-Bolado G . RGMb controls aggregation and migration of Neogenin-positive cells in vitro and in vivo. Mol Cell Neurosci. 2009; 43(2):222-31. DOI: 10.1016/j.mcn.2009.11.003. View

18.

Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S . Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019; 216(4):982-1000. PMC: 6446862. DOI: 10.1084/jem.20180870. View

19.

Gao Y, Nihira N, Bu X, Chu C, Zhang J, Kolodziejczyk A . Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol. 2020; 22(9):1064-1075. PMC: 7484128. DOI: 10.1038/s41556-020-0562-4. View

20.

Gill A, Wang P, Lee J, Hudson W, Ando S, Araki K . PD-1 blockade increases the self-renewal of stem-like CD8 T cells to compensate for their accelerated differentiation into effectors. Sci Immunol. 2023; 8(86):eadg0539. PMC: 10798572. DOI: 10.1126/sciimmunol.adg0539. View